Management of eGFR 40 mL/min/1.73 m²
A patient with eGFR 40 mL/min/1.73 m² has Stage 3b CKD (moderate renal insufficiency) and requires comprehensive cardiovascular and kidney protection through specific pharmacologic interventions, blood pressure control, and nephrology monitoring. 1, 2
Classification and Risk Stratification
Your patient falls into GFR category G3b (30-44 mL/min/1.73 m²), which represents moderate renal insufficiency 1. The management intensity depends critically on albuminuria status—you must measure urine albumin-to-creatinine ratio (ACR) immediately if not already done, as this determines both prognosis and treatment strategy 3, 2.
First-Line Pharmacologic Interventions
For Type 2 Diabetes Patients
Initiate an SGLT2 inhibitor immediately if the patient has type 2 diabetes, regardless of albuminuria level 4, 5. Start the SGLT2i now at eGFR 40 and continue it even as eGFR declines below 20 mL/min/1.73 m² until dialysis initiation 3, 2. This provides both kidney and cardiovascular protection independent of glucose control.
Add RAS inhibition (ACEi or ARB) if albuminuria is present (ACR ≥30 mg/g or ≥3 mg/mmol), particularly if hypertension coexists 3, 2. Use maximum tolerated doses—the proven benefits in trials were achieved at these doses 2.
Consider adding a nonsteroidal MRA (finerenone) if albuminuria persists >30 mg/g despite maximum tolerated RASi, and only if serum potassium is consistently ≤4.8 mmol/L 2, 5. This provides additional cardiovascular and kidney protection in high-risk patients with type 2 diabetes.
Add a GLP-1 receptor agonist if glycemic targets aren't met with metformin and SGLT2i, prioritizing agents with proven cardiovascular benefits (liraglutide, semaglutide) 4, 5.
For Non-Diabetic Patients
Start RASi (ACEi or ARB) if severely increased albuminuria (ACR ≥300 mg/g or ≥30 mg/mmol) is present 2. For moderately increased albuminuria (ACR 30-300 mg/g), RASi is also recommended though with slightly less strong evidence 2.
Initiate an SGLT2 inhibitor even without diabetes if ACR ≥200 mg/g (≥20 mg/mmol) or if heart failure is present 2, 5. The kidney-protective effects extend beyond diabetes.
Universal Interventions
Start a statin for all patients with CKD at this level, regardless of diabetes status 3, 4. This reduces cardiovascular risk, which is substantially elevated at eGFR 40.
Blood Pressure Management
Target <130/80 mmHg for all patients with CKD 4. If severely elevated albuminuria (≥300 mg/g) is present, consider even lower targets. Use RASi as first-line if albuminuria exists; otherwise, dihydropyridine calcium channel blockers or diuretics are appropriate 3.
Critical monitoring point: Check serum creatinine and potassium 2-4 weeks after initiating or increasing RASi doses 2. Continue RASi unless creatinine rises >30% within 4 weeks or uncontrolled hyperkalemia develops 2, 4.
Medication Dosing Adjustments
At eGFR 40, multiple medications require dose adjustments 6:
- Metformin: Safe to continue but reassess risk-benefit; do not initiate if eGFR <45 4, 6
- NSAIDs: Avoid entirely 6
- Opioids: Reduce doses 6
- Many antibiotics: Adjust based on specific agent 6
Monitoring Frequency
Measure serum creatinine and potassium every 3-6 months at baseline 4. If albuminuria is present, this represents "orange zone" risk requiring twice-yearly monitoring 4. After initiating kidney-protective medications, increase monitoring frequency temporarily.
Recheck urine ACR every 3-6 months if albuminuria is present. A reduction of ≥30% in albuminuria indicates effective treatment and slower CKD progression 4.
Nephrology Referral
Refer to nephrology now since eGFR is <45 mL/min/1.73 m² 4, 7. While you can initiate the above interventions, nephrology involvement at this stage helps with:
- Identifying reversible causes of CKD
- Optimizing complex medication regimens
- Planning for potential progression
- Educating about kidney replacement therapy options
The referral is particularly urgent if eGFR is declining rapidly, albuminuria is worsening, or uncertainty exists about CKD etiology 4.
Additional Considerations
Dietary protein: Target 0.8 g/kg/day for non-dialysis CKD 4. Avoid routine severe protein restriction.
Smoking cessation: Mandatory—reduces CKD progression risk by 9-11% 8.
Avoid nephrotoxins: Review all medications and supplements; eliminate unnecessary nephrotoxic agents 9.
Metabolic acidosis: Monitor serum bicarbonate; consider treatment if <18 mmol/L to slow progression 5.
Common Pitfalls
Do not discontinue RASi for creatinine increases <30% within the first month—this is expected hemodynamic effect, not kidney injury 2, 4. The long-term kidney protection outweighs this transient change.
Do not combine ACEi + ARB—this increases adverse events without additional benefit 2, 7.
Do not withhold SGLT2i due to initial eGFR dip—the reversible decrease on initiation is not an indication to stop 2, 5.
Do not delay SGLT2i initiation waiting for "worse" kidney function—start now at eGFR 40 to maximize kidney-protective years 3, 2.